Citation Impact
Citing Papers
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2009 Standout
The “cancer immunogram”
2016 Science
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
2015
Cancer statistics, 2022
2022 Standout
Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation
2011
Cancer statistics, 2023
2023 Standout
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
2019
Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
2013
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Idiopathic pulmonary fibrosis
2017 Standout
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
2021
Breast cancer
2016 Standout
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Natural products: A continuing source of novel drug leads
2013 Standout
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia
2015
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer
2015
Marine natural products
1990 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Marine natural products
2009
The Thrombospondins
2011 Standout
Hepatocellular carcinoma
2021 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
2013
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
2007
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
2013
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Immune checkpoint inhibitors in melanoma
2021
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Novel bioactive glycerol-based lysophospholipids: New data – New insight into their function
2012
Pyroptosis: mechanisms and diseases
2021 Standout
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study
2009
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
From the Sea to Anticancer Therapy
2011
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
2013
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
2016
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Pre-eclampsia
2010 Standout
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
2016
Targeting Echinococcus multilocularis Stem Cells by Inhibition of the Polo-Like Kinase EmPlk1
2014
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
2009
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
2017
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment
2016
The molecular landscape of head and neck cancer
2018 Standout
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
2017 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Renal cell carcinoma
2017 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Tumor Angiogenesis
2008 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Diving for drugs: tunicate anticancer compounds
2012
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
2014
Neanderthal ancestry drives evolution of lipid catabolism in contemporary Europeans
2014 StandoutNobel
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
2009
Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
2007
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
2015
Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
2013
Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological Potential
2007 Standout
Echinococcosis: Advances in the 21st Century
2019 Standout
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
2020
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant
2013 StandoutNobel
Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
2013
Chimeric Antigen Receptor Therapy
2018 Standout
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
2015
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck
2017
Cancer treatment and survivorship statistics, 2019
2019 Standout
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Characterization of DNA Methylation in Circulating Tumor Cells
2015
Drug Resistance in Cancer: An Overview
2014 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
2013
Works of Pascal Wolter being referenced
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients
2015
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
2012
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
2006
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
2012
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
2010
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
2008
Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option
2012
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
2009
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
2008
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
2014
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
2011
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
2018
t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34
2011
MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma
2014
Prognostic impact of baseline serum C ‐reactive protein in patients with metastatic renal cell carcinoma ( RCC ) treated with sunitinib
2013
Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma
2007
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
2015
A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance
2012
Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
2014
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
2010
Nemo: a Phase 3 Trial of Binimetinib (Mek162) Versus Dacarbazine in Patients with Advanced Nras-Mutant Melanoma Who are Untreated or Have Progressed After Any Number of Immunotherapy Regimens
2014
Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib.
2013
Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation
2006